文献速递浆细胞疾病

AL型淀粉样变性患者自体干细胞移植后二线治疗时机的界定

Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
PubMed 文献 · Blood · 2017-08-14

该回顾性研究纳入梅奥诊所235例初治接受自体干细胞移植的免疫球蛋白轻链型淀粉样变性患者,评估复发或进展模式及重启治疗时机。自体干细胞移植至二线治疗的中位时间为24.3个月;重启治疗时32%患者dFLC<5 mg/dL,63%符合器官复发或进展标准;二线治疗时存在器官进展者生存较差。

要点

  • 自体干细胞移植至二线治疗的中位时间为24.3个月。
  • 重启治疗时32%患者dFLC<5 mg/dL,63%符合器官复发或进展标准。
  • 从非常好的部分缓解(VGPR)或更好缓解复发者,血液学复发或进展后至器官进展时间更长(24.2 vs 3.2个月,P = .007)。

核心结论

  • 自体干细胞移植至二线治疗的中位时间为24.3个月。
  • 二线治疗时存在器官进展的患者生存较差。
  • 重启治疗时dFLC>5 mg/dL与风险相关。
  • 从VGPR或更好缓解复发者,血液学复发或进展后至器官进展的时间长于其他患者(24.2 vs 3.2个月,P = .007)。
  • 作者认为,测试新型浆细胞定向化疗的研究最佳候选者可能是从VGPR或更好缓解复发(诊断时dFLC>5 mg/dL)或对先前治疗反应不足的患者。

研究设计与样本

  • 回顾性研究,纳入235例在梅奥诊所初治接受自体干细胞移植的免疫球蛋白轻链型淀粉样变性患者。
  • 评估复发或进展模式及重启治疗的时机。

主要发现

  • 自体干细胞移植至二线治疗的中位时间为24.3个月。
  • 重启治疗时,游离轻链差值(dFLC)中位数为9.9 mg/dL(为诊断值的42%)。
  • 重启治疗时32%患者dFLC<5 mg/dL。
  • 重启治疗时63%患者符合器官复发或进展标准。
  • 重启治疗指征:临床怀疑复发或进展10%;仅血液学复发或进展23%;仅器官复发或进展32%;血液学和器官复发或进展31%;对自体干细胞移植反应欠佳、二线治疗作为巩固4%。

关键数值与推荐

  • 重启治疗时dFLC>5 mg/dL与风险相关。
  • 从VGPR或更好缓解复发者,血液学复发或进展后至器官进展时间为24.2个月,其他患者为3.2个月(P = .007)。

临床怎么用

  • 作者认为,测试新型浆细胞定向化疗的研究最佳候选者可能是从VGPR或更好缓解复发(诊断时dFLC>5 mg/dL)或对先前治疗反应不足的患者。
  • 作者认为该策略可在评估血液学反应的同时避免有害器官进展的风险。
  • 作者认为可能有必要实施更严格的进展标准。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Among patients with immunoglobulin light chain (AL) amyloidosis, there is little consensus on when reinstitution of chemotherapy should occur. We conducted a retrospective study to evaluate the patterns of relapse or progression (R/P) and the timing of reinitiating therapy among 235 patients initially treated with autologous stem cell transplant (ASCT) at Mayo Clinic. The median time from ASCT to second-line therapy was 24.3 months. At the time of restarting therapy, median difference of free light chain (dFLC) was 9.9 mg/dL (42% of diagnosis value), 32% had a dFLC <5 mg/dL, and 63% met criteria for organ R/P. The indications for retreatment were (1) clinical suspicion of R/P, 10%; 92) hematologic R/P only, 23%; (3) organ R/P only, 32%; (4) both hematologic and organ R/P, 31%; and (5) suboptimal response to ASCT and second-line therapy as consolidation, 4%. Patients with organ progression at the time of second-line therapy had inferior survival. Although a dFLC of >5 mg/dL at the time of reinstituting therapy was associated with risk, patients relapsing from very good partial response (VGPR) or better had a longer time to develop organ progression after hematologic R/P (24.2 vs 3.2 months, P = .007). These data suggest that the best candidates for clinical trials testing novel plasma cell-directed chemotherapy beyond first line may be those patients who are either relapsing from VGPR or better (dFLC at diagnosis was >5 mg/dL) or having inadequate response to prior therapy. This strategy should allow for hematologic response assessment while avoiding the risk of deleterious organ progression. Implementation of more stringent progression criteria may also be warranted.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hwa YL, Warsame R, Gertz MA, et al. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. Blood. 2017. PMID: 28807981. doi:10.1182/blood-2017-05-783415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。